Financials data is unavailable for this security.
Inc stmt in EURIncome statement in EUR
Year on year
Bayer AG had relatively flat revenues (46.09bn to 46.77bn), though the company grew net income 10.24% from 4.11bn to 4.53bn. A reduction in the cost of goods sold as a percentage of sales from 45.65% to 43.39% was a component in the net income growth despite flat revenues.
|Net profit margin||10.80%|
|Return on assets||6.43%|
|Return on equity||16.72%|
|Return on investment||8.57%|
Cash flow in EUR
Bayer AG did not generate a significant amount of cash. However, the company earned 9.09bn from its operations for a Cash Flow Margin of 19.44%. In addition the company used 8.73bn on investing activities and also paid 350.00m in financing cash flows.
|Cash flow per share||9.59|
|Price/Cash flow per share||12.23|
|Book value per share||38.58|
|Tangible book value per share||4.54|
Balance sheet in EUR
|Total debt/total equity||0.5648|
|Total debt/total capital||0.3462|
Growth rates in EUR
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 8.00% and 5.21%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
|Div yield(5 year avg)||1.88%|
|Div growth rate (5 year)||10.35%|
|Payout ratio (TTM)||46.66%|
|EPS growth(5 years)||11.38|
|EPS (TTM) vs |
TTM 1 year ago